Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2021; 13(9): 1109-1120
Published online Sep 15, 2021. doi: 10.4251/wjgo.v13.i9.1109
Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system
Zoltan Herold, A Marcell Szasz, Magdolna Dank
Zoltan Herold, A Marcell Szasz, Magdolna Dank, Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest H-1083, Hungary
Author contributions: Herold Z and Szasz AM searched the literature and drafted initial manuscript; Dank M provided further editing and comments; All authors have read and agreed to the published version of the manuscript.
Supported by The UNKP-20-4-I New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund.
Conflict-of-interest statement: The authors declare that they have no conflicting interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Magdolna Dank, MD, PhD, Professor, Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Tomo u. 25-29, Budapest H-1083, Hungary. dank.magdolna@med.semmelweis-univ.hu
Received: February 22, 2021
Peer-review started: February 22, 2021
First decision: April 19, 2021
Revised: April 29, 2021
Accepted: July 23, 2021
Article in press: July 23, 2021
Published online: September 15, 2021
Core Tip

Core Tip: Adjuvant hyperthermia is beneficial in hepatopancreatobiliary cancers because of its direct and indirect antitumor effects. Increased treatment response, prolonged survival, and improved laboratory and quality of life data have been observed in several randomized and observational clinical trials of various hyperthermia methods. The use of hyperthermia in cancer care is not yet routine. In this review, the clinical data on hyperthermia in hepatopancreatobiliary tumors is summarized, focusing mainly on results that have the most clinical and research interest.